This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Michele B. Wagner, MD
Beth Israel Deaconess Medical Center Boston, Mass

JAMA. 1997;278(20):1660.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—The article by Dr Hebert and colleagues,¹ which reviewed acute cardiovascular events and deaths in trials of statin drugs, does not comment on the outcome of the female patients included in these trials. Of the 13 secondary prevention trials, 1 included no female patients, and only 3 (Expanded Clinical Evaluation of Lovastatin [EXCE L], Scandinavian Simvastatin Survival Study [4S], and Cholesterol and Recurrent Events [CARE]) enrolled more than 100 female patients and followed up patients for more than 1 year. The EXCEL trial^2,3 enrolled approximately 3389 female patients and the follow-up period was 48 weeks. However, patients were divided into 5 treatment groups, with no significant differences in adverse outcomes between the groups. No power calculation was performed and the authors did not report data on female patients separately. A total of 827 female patients were enrolled in the 4S study,⁴ with a . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?